Journal Article Review Epublish 2 citations
PubMed: 42327580 DOI: 10.7150/jca.134550
Emerging Oncolytic Viruses: Beyond Adenoviruses and Herpes Simplex Virus.
J Cancer 17(6):1229-1247
Authors: Santosh Chokkakula, Chengliang Yin, Bing Yang, Siomui Chong, Balaji Pathakumari, Yi-Quan Zhang, Pangi Vijaya Nirmala, Khin Wee Lai, Bommireddy Naveen, Quan Tang
Affiliations
- Department of Microbiology, Chungbuk National University College of Medicine and Medical Research Institute, Cheongju, Chungbuk, 28644, South Korea.
- Department of Biomedical Engineering, Faculty of Engineering, Universiti Malaya, Kuala Lumpur, 50603, Malaysia.
- Department of Medical and Nursing Science, International College, Krirk University, Bangkok 10220, Thailand. Department of Cell Biology, College of Basic Medical Sciences, Tianjin Medical University, Tianjin, China.
- Department of Dermatology, The University of Hong Kong-Shenzhen Hospital, Shenzhen, 518053, China. Department of Dermatology, The First Affiliated Hospital of Jinan University & Jinan University Institute of Dermatology, Guangzhou, 510630, China.
- Division of Pulmonary and Critical Care Medicine, Department of Medicine, Mayo Clinic, Rochester, MN, 55905, USA.
- Department of Cell Biology, College of Basic Medical Sciences, Tianjin Medical University, Tianjin, China.
- School of Life & Health Sciences Adikavi Nannaya University Rajahmundry, Andhra Pradesh India, 533296, India.
- Department of Chemical and Biological Engineering, Gachon University, Seongnam-Si, Gyeonggi-do, Republic of Korea.
- Research Laboratory, Shenzhen Baoan Women's and Children's Hospital, Shenzhen, Guangdong, China.
Abstract
Oncolytic virotherapy represents an innovative therapeutic modality in oncology, exploiting the selective tropism of viruses to target and eradicate malignant cells. Unlike conventional cancer treatments such as chemotherapy and radiotherapy, oncolytic viruses (OVs) exhibit a dual mechanism of action: direct tumor cell lysis and potent immune activation. This approach transforms tumors into in situ vaccines, generating durable anti-tumor immune memory. The field has garnered substantial attention following the regulatory approval of talimogene laherparepvec (T-VEC), a genetically engineered herpes simplex virus, for metastatic melanoma treatment-a watershed moment in oncolytic virotherapy. Recent advances in genetic engineering have significantly enhanced OV specificity and efficacy, addressing critical challenges including tumor-selective targeting and immune evasion. This review comprehensively examines the complex mechanisms underlying OV therapeutic action, clinical applications, and recent developments that position oncolytic virotherapy as a transformative strategy in contemporary cancer treatment.
MeSH
Cells, Herpes Simplex, Adenoviridae, Neoplasms, Simplexvirus, Oncolytic Viruses, Oncolytic Virotherapy, Viruses, Immunity, Therapeutics